Código QR (código de barras bidimensional)

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

Abstract Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological and developmental characteristics of...

ver descrição completa

Na minha lista:
Principais autores: Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2025-08-01
coleção:BMC Gastroenterology
Assuntos:
Infliximab
Adalimumab
Adverse event
Pharmacovigilance
Pediatric
Inflammatory bowel diseases
Acesso em linha:https://doi.org/10.1186/s12876-025-04154-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados